MADRID -- Vericiguat (Verquvo) missed the mark for reducing heart failure (HF) hospitalizations but lowered the risk of cardiovascular death in patients with HF with reduced ejection fraction (HFrEF) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback